News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,074 Results
Type
Article (42245)
Company Profile (436)
Press Release (670393)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208706)
Career Advice (2021)
Deals (36002)
Drug Delivery (104)
Drug Development (83562)
Employer Resources (173)
FDA (16419)
Job Trends (15089)
News (352731)
Policy (33065)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50926)
ALS (92)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (127)
Approvals (16405)
Artificial intelligence (253)
Autoimmune disease (24)
Automation (15)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (270)
Cancer (2134)
Cardiovascular disease (178)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (424)
Cervical cancer (19)
Clinical research (67629)
Collaboration (831)
Compensation (512)
Complete response letters (24)
COVID-19 (2642)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2079)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (261)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (123)
Drug pricing (105)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87560)
Editorial (37)
Employer branding (21)
Employer resources (147)
Events (115424)
Executive appointments (704)
FDA (17612)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (749)
Gene editing (109)
Generative AI (20)
Gene therapy (311)
GLP-1 (736)
Government (4489)
Grass and pollen (4)
Guidances (50)
Healthcare (19143)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (27)
Infectious disease (2785)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (91)
Interviews (311)
IPO (16775)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (35)
Layoffs (487)
Leadership (17)
Legal (7982)
Liver cancer (73)
Lung cancer (308)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (286)
MASH (65)
Medical device (13492)
Medtech (13497)
Mergers & acquisitions (19733)
Metabolic disorders (690)
Multiple sclerosis (77)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1962)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2557)
Now hiring (37)
Obesity (375)
Opinion (222)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (80)
Parkinson's disease (153)
Partnered (21)
Patents (222)
Patient recruitment (100)
Peanut (47)
People (58578)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21249)
Phase II (29838)
Phase III (22071)
Pipeline (1139)
Policy (135)
Postmarket research (2601)
Preclinical (9067)
Press Release (67)
Prostate cancer (101)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (395)
Real estate (6014)
Recruiting (66)
Regulatory (22664)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (86)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2218)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (22)
The Weekly (47)
United States (22516)
Vaccines (684)
Venture capitalists (38)
Weight loss (250)
Women's health (36)
Worklife (16)
Date
Today (100)
Last 7 days (486)
Last 30 days (2535)
Last 365 days (34042)
2025 (9357)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (39163)
Australia (6523)
California (5890)
Canada (1945)
China (499)
Colorado (259)
Connecticut (275)
Delaware (136)
Europe (85567)
Florida (859)
Georgia (202)
Idaho (57)
Illinois (527)
India (25)
Indiana (302)
Iowa (10)
Japan (150)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (875)
Massachusetts (4496)
Michigan (217)
Minnesota (384)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (59)
New Hampshire (66)
New Jersey (1684)
New Mexico (30)
New York (1667)
North Carolina (1003)
North Dakota (7)
Northern California (2557)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1313)
Puerto Rico (11)
Rhode Island (30)
South America (1110)
South Carolina (19)
South Dakota (1)
Southern California (2218)
Tennessee (98)
Texas (874)
Utah (173)
Virginia (140)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
713,074 Results for "mabwell therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 27, 2025
·
5 min read
Press Releases
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
April 2, 2025
·
4 min read
Press Releases
Mabwell’s Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation
January 9, 2025
·
5 min read
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer.
May 13, 2024
·
6 min read
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London
Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, published “Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor” as poster presentation from March 12 to 15, 2024 at the 14th World ADC London.
March 21, 2024
·
6 min read
Press Releases
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
November 8, 2024
·
4 min read
Press Releases
Mabwell’s Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA
November 15, 2024
·
5 min read
Drug Development
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
Mabwell presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10, 2024.
April 16, 2024
·
7 min read
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting
Mabwell, an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple advanced solid tumors, which will be reported as an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.
May 24, 2024
·
7 min read
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Mabwell announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held in San Diego, from April 5-10, 2024.
March 12, 2024
·
7 min read
1 of 71,308
Next
